Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
GSK to highlight continued progress in oncology pipeline and portfolio with data presented at ESMO
GSK to highlight continued progress in oncology pipeline and portfolio with data presented at ESMO
-
SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data
-
GSK announces “Ask2BSure” public health awareness campaign for meningitis B vaccination
GSK launches “Ask2BSure,” to encourage parents to talk with their child’s doctor to be sure if they have received meningitis B vaccination.
-
GSK receives FDA accelerated approval for JEMPERLI (dostarlimab-gxly) for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumors
GSK receives FDA accelerated approval for JEMPERLI for adult patients with mismatch repair-deficient recurrent or advanced solid tumors
-
Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone
-
GSK files for licensure of MMR vaccine in the US
GSK seeks US approval of PRIORIX vaccine licensed in more than 100 countries.
-
GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps
Fourth indication for mepolizumab in the US for eosinophil-driven diseases.
-
GSK delivers strong Q2 sales of £8.1 billion, +6% AER, +15% CER Total EPS 27.9p -39% AER, -28% CER; Adjusted EPS 28.1p +46% AER +71% CER
Sales growth driven by strong commercial execution and favourable prior year comparison
-
Shingrix approved in the US for prevention of shingles in immunocompromised adults
Shingrix approved in the US for prevention of shingles in immunocompromised adults
-
GSK begins shipping another record supply of influenza vaccine for 2021-22 season in US
GSK increases its volume of influenza vaccines in 2021 to support immunization during pandemic.
-
ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs
ViiV Healthcare today presented 48-week data from the SALSA study at the International AIDS Society Conference 2021
-
ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19
ViiV Healthcare today presented positive findings from the CUSTOMIZE trial
-
ViiV Healthcare to present new data from diverse portfolio and pipeline of 2-drug and long-acting regimens for HIV treatment and prevention at IAS 2021
Data to be presented underscore the commitment to developing innovative treatment and prevention options
-
GSK announces positive headline results from five Phase 3 studies of daprodustat for patients with anaemia due to chronic kidney disease
Full results to be presented at a medical meeting later this year
-
GSK and Alector announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases
GSK and Alector to co-develop progranulin-elevating monoclonal antibodies, AL001 and AL101, for a range of neurodegenerative diseases
-
Elliott Advisors (UK) letter to GSK
The Board of GSK notes the letter issued by Elliott Advisors (UK) Limited (“Elliott”) on 1 July
-
New GSK to deliver step-change in growth and performance over next ten years driven by high-quality Vaccines and Specialty Medicines portfolio and late-stage pipeline
New GSK to positively impact health of >2.5 billion people next 10 years
-
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV
Halozyme's technology provides more "shots on goal" to create ultra long-acting HIV medicines with dosing intervals of 3 months or longer
-
GSK and Vir Biotechnology announce continuing progress of the COMET clinical development programme for sotrovimab
U.S. National Institutes of Health (NIH) COVID-19 Treatment Guidelines updated to recommend use of sotrovimab.
-
GSK and iTeos Therapeutics announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations
GSK now has the leading portfolio of antibodies targeting the CD226 axis - a key target for next-generation immuno-oncology therapies
